Man Group PLC Glycomimetics Inc Transaction History

Man Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $382,140 - $523,007	149,859 New	149,859 $449,000
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.9 $9,680 - $15,840	17,600 New	17,600 $10,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $60,264 - $88,722	-27,900 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $84,243 - $123,013	-29,150 Reduced 51.1%	27,900 $84,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $153,464 - $241,892	57,050 New	57,050 $215,000
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $1.39 Million - $6.37 Million	-495,515 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $540,123 - $668,529	-50,955 Reduced 9.32%	495,515 $5.91 Million
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $487,203 - $657,431	-48,916 Reduced 8.22%	546,470 $6.81 Million
Q4 2018 Feb 14, 2019	BUY	$8.47 - $14.71 $1.55 Million - $2.7 Million	183,391 Added 44.51%	595,386 $5.64 Million
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $4.87 Million - $6.08 Million	355,329 Added 627.06%	411,995 $5.93 Million
Q2 2018 Aug 14, 2018	BUY	$14.63 - $19.19 $829,023 - $1.09 Million	56,666 New	56,666 $914,000

28.9M

51K

1.4K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.